Vanguard Group Inc. Buys 83,783 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Vanguard Group Inc. increased its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 4.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,832,535 shares of the company’s stock after purchasing an additional 83,783 shares during the period. Vanguard Group Inc. owned approximately 0.07% of Castle Biosciences worth $48,837,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Janus Henderson Group PLC acquired a new position in shares of Castle Biosciences during the 3rd quarter worth about $261,000. State Street Corp boosted its stake in Castle Biosciences by 9.8% during the 3rd quarter. State Street Corp now owns 680,001 shares of the company’s stock worth $19,394,000 after acquiring an additional 60,924 shares during the last quarter. Y Intercept Hong Kong Ltd grew its holdings in Castle Biosciences by 3.6% during the third quarter. Y Intercept Hong Kong Ltd now owns 24,206 shares of the company’s stock valued at $690,000 after purchasing an additional 845 shares during the period. Barclays PLC increased its stake in Castle Biosciences by 310.7% in the third quarter. Barclays PLC now owns 52,301 shares of the company’s stock valued at $1,491,000 after purchasing an additional 39,567 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Castle Biosciences by 1.1% in the third quarter. Geode Capital Management LLC now owns 624,683 shares of the company’s stock worth $17,820,000 after purchasing an additional 7,004 shares during the period. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences Price Performance

CSTL stock opened at $19.70 on Friday. The stock has a 50-day moving average price of $22.34 and a two-hundred day moving average price of $27.10. Castle Biosciences, Inc. has a 1 year low of $16.97 and a 1 year high of $35.84. The stock has a market cap of $568.13 million, a PE ratio of 98.50 and a beta of 1.11. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02.

Analyst Upgrades and Downgrades

CSTL has been the subject of several research analyst reports. Stephens reissued an “overweight” rating and issued a $41.00 price target on shares of Castle Biosciences in a report on Thursday, January 2nd. Guggenheim set a $30.00 target price on Castle Biosciences and gave the stock a “buy” rating in a report on Friday, March 28th. Finally, Robert W. Baird increased their price target on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $38.75.

Insider Transactions at Castle Biosciences

In other news, insider Derek J. Maetzold sold 986 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $28.03, for a total value of $27,637.58. Following the sale, the insider now owns 80,818 shares of the company’s stock, valued at $2,265,328.54. The trade was a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total transaction of $221,613.39. The disclosure for this sale can be found here. Insiders sold 35,071 shares of company stock valued at $775,682 over the last three months. Company insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.